Age-related immune response to pneumococcal polysaccharide vaccination: lessons for the clinic

References

• Ludwig E, Bonanni P, Rohde G, et al. The remaining challenges of pneumococcal disease in adults. Eur Respir Rev 2012;21(123):57-65
   PubMedGoogle Scholar
• Blasi F, Mantero M, Santus P, Tarsia P. Understanding the burden of pneumococcal disease in adults. Clin Microbiol Infect 2012;18(Suppl 5):7-14
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009;374(9693):893-902
   PubMed Web of Science ®Google Scholar
• Wroe PC, Finkelstein JA, Ray GT, et al. Aging population and future burden of pneumococcal pneumonia in the United States. J Infect Dis 2012;205(10):1589-92
   PubMed Web of Science ®Google Scholar
• Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: the challenges ahead. Lancet 2009;374(9696):1196-208
   PubMed Web of Science ®Google Scholar
• Kadioglu A, Weiser JN, Paton JC, Andrew PW. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat Rev Microbiol 2008;6(4):288-301
   PubMed Web of Science ®Google Scholar
• Henriques-Normark B, Tuomanen EI. The pneumococcus: epidemiology, microbiology, and pathogenesis. Cold Spring Harb Perspect Med 2013;3(7):a010215
   PubMed Web of Science ®Google Scholar
• Moffitt KL, Malley R. Next generation pneumococcal vaccines. Curr Opin Immunol 2011;23(3):407-13
   PubMed Web of Science ®Google Scholar
• Feldman C, Anderson R. Bacteraemic pneumococcal pneumonia: current therapeutic options. Drugs 2011;71(2):131-53
   PubMedGoogle Scholar
• van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 2009;374(9700):1543-56
   PubMed Web of Science ®Google Scholar
• Centers for Disease CP. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae, 2012. 2013. Available from: www.cdc.gov/abcs/reports-findings/survreports/spneu12.pdf
   Google Scholar
• Weiss K, Tillotson GS. The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia. Chest 2005;128(2):940-6
   PubMedGoogle Scholar
• Chokshi R, Restrepo MI, Weeratunge N, et al. Monotherapy versus combination antibiotic therapy for patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2007;26(7):447-51
   PubMed Web of Science ®Google Scholar
• Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004;170(4):440-4
   PubMed Web of Science ®Google Scholar
• Blasi F, Ostermann H, Racketa J, et al. Early versus later response to treatment in patients with community-acquired pneumonia: analysis of the REACH study. Respir Res 2014;15:6
   Google Scholar
• Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-72
   PubMed Web of Science ®Google Scholar
• Rodriguez A, Lisboa T, Blot S, et al. Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough. Intensive Care Med 2009;35(3):430-8
   PubMed Web of Science ®Google Scholar
• Robbins JB, Austrian R, Lee CJ, et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 1983;148(6):1136-59
   PubMed Web of Science ®Google Scholar
• Mond JJ, Lees A, Snapper CM. T cell-independent antigens type 2. Annu Rev Immunol 1995;13:655-92
   PubMed Web of Science ®Google Scholar
• Westerink MA, Schroeder HWJr, Nahm MH. Immune Responses to pneumococcal vaccines in children and adults: rationale for age-specific vaccination. Aging Dis 2012;3(1):51-67
   PubMed Web of Science ®Google Scholar
• Advisory Committee on Immunization P. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000;49(RR-9):1-35
   Google Scholar
• Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000;19(3):187-95
   PubMed Web of Science ®Google Scholar
• Jones RN, Jacobs MR, Sader HS. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia. Int J Antimicrob Agents 2010;36(3):197-204
   PubMed Web of Science ®Google Scholar
• Centers for Disease C, Prevention. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010;59(9):258-61
   PubMedGoogle Scholar
• Centers for Disease C, Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2013;62(25):521-4
   PubMedGoogle Scholar
• Centers for Disease C, Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012;61(40):816-19
   PubMedGoogle Scholar
• Centers for Disease C, Prevention, Advisory Committee on Immunization P. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010;59(34):1102-6
   PubMedGoogle Scholar
• Centers for Disease C, Prevention. Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. MMWR Morb Mortal Wkly Rep 2012;61(21):394-5
   PubMedGoogle Scholar
• Nuorti JP, Whitney CG; Centers for Disease C, Prevention. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010;59(RR-11):1-18
   PubMedGoogle Scholar
• Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013;1:CD000422
   PubMed Web of Science ®Google Scholar
• Maruyama T, Taguchi O, Niederman MS, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ 2010;340:c1004
   PubMed Web of Science ®Google Scholar
• Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged >/= 60 years: 3 years of follow-up in the CAPAMIS study. Clin Infect Dis 2014;58(7):909-17
   PubMed Web of Science ®Google Scholar
• Grabenstein JD, Manoff SB. Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults. Vaccine 2012;30(30):4435-44
   PubMed Web of Science ®Google Scholar
• Centers for Disease CP. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997;46(RR-8):1-24
   Google Scholar
• Jodar L, Butler J, Carlone G, et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 2003;21(23):3265-72
   PubMed Web of Science ®Google Scholar
• Romero-Steiner S, Frasch CE, Carlone G, et al. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol 2006;13(2):165-9
   PubMedGoogle Scholar
• Lee H, Nahm MH, Kim KH. The effect of age on the response to the pneumococcal polysaccharide vaccine. BMC Infect Dis 2010;10:60
   PubMedGoogle Scholar
• Andrews NJ, Waight PA, Burbidge P, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a post-licensure indirect cohort study. Lancet Infect Dis 2014;14(9):839-46
   PubMed Web of Science ®Google Scholar
• Leggat DJ, Thompson RS, Khaskhely NM, et al. The immune response to pneumococcal polysaccharides 14 and 23F among elderly individuals consists predominantly of switched memory B cells. J Infect Dis 2013;208(1):101-8
   PubMedGoogle Scholar
• Schenkein JG, Park S, Nahm MH. Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency. Vaccine 2008;26(43):5521-6
   PubMed Web of Science ®Google Scholar
• Simell B, Vuorela A, Ekstrom N, et al. Aging reduces the functionality of anti-pneumococcal antibodies and the killing of Streptococcus pneumoniae by neutrophil phagocytosis. Vaccine 2011;29(10):1929-34
   PubMed Web of Science ®Google Scholar
• Park S, Nahm MH. Older adults have a low capacity to opsonize pneumococci due to low IgM antibody response to pneumococcal vaccinations. Infect Immun 2011;79(1):314-20
   PubMed Web of Science ®Google Scholar
• Romero-Steiner S, Musher DM, Cetron MS, et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis 1999;29(2):281-8
   PubMed Web of Science ®Google Scholar
• Manoff SB, Liss C, Caulfield MJ, et al. Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged 65 > or = years. J Infect Dis 2010;201(4):525-33
   PubMed Web of Science ®Google Scholar
• Ademokun A, Wu YC, Martin V, et al. Vaccination-induced changes in human B-cell repertoire and pneumococcal IgM and IgA antibody at different ages. Aging Cell 2011;10(6):922-30
   PubMed Web of Science ®Google Scholar
• Shi Y, Yamazaki T, Okubo Y, et al. Regulation of aged humoral immune defense against pneumococcal bacteria by IgM memory B cell. J Immunol 2005;175(5):3262-7
   PubMed Web of Science ®Google Scholar
• Khaskhely N, Mosakowski J, Thompson RS, et al. Phenotypic analysis of pneumococcal polysaccharide-specific B cells. J Immunol 2012;188(5):2455-63
   PubMedGoogle Scholar
• Kolibab K, Smithson SL, Rabquer B, et al. Immune response to pneumococcal polysaccharides 4 and 14 in elderly and young adults: analysis of the variable heavy chain repertoire. Infect Immun 2005;73(11):7465-76
   PubMed Web of Science ®Google Scholar
• Serpa JA, Valayam J, Musher DM, et al. V(H)3 antibody response to immunization with pneumococcal polysaccharide vaccine in middle-aged and elderly persons. Clin Vaccine Immunol 2011;18(3):362-6
   PubMedGoogle Scholar
• Smithson SL, Kolibab K, Shriner AK, et al. Immune response to pneumococcal polysaccharides 4 and 14 in elderly and young adults: analysis of the variable light chain repertoire. Infect Immun 2005;73(11):7477-84
   PubMedGoogle Scholar
• Park S, Nahm MH. L-rhamnose is often an important part of immunodominant epitope for pneumococcal serotype 23F polysaccharide antibodies in human sera immunized with PPV23. PLoS One 2013;8(12):e83810
   PubMed Web of Science ®Google Scholar
• Kruetzmann S, Rosado MM, Weber H, et al. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med 2003;197(7):939-45
   PubMed Web of Science ®Google Scholar
• Weller S, Braun MC, Tan BK, et al. Human blood IgM “memory” B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood 2004;104(12):3647-54
   PubMedGoogle Scholar
• Cerutti A, Cols M, Puga I. Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes. Nat Rev Immunol 2013;13(2):118-32
   PubMed Web of Science ®Google Scholar
• Wu YC, Kipling D, Leong HS, et al. High-throughput immunoglobulin repertoire analysis distinguishes between human IgM memory and switched memory B-cell populations. Blood 2010;116(7):1070-8
   PubMedGoogle Scholar
• Weller S, Mamani-Matsuda M, Picard C, et al. Somatic diversification in the absence of antigen-driven responses is the hallmark of the IgM+ IgD+ CD27+ B cell repertoire in infants. J Exp Med 2008;205(6):1331-42
   PubMedGoogle Scholar
• Tsuiji M, Yurasov S, Velinzon K, et al. A checkpoint for autoreactivity in human IgM+ memory B cell development. J Exp Med 2006;203(2):393-400
   PubMed Web of Science ®Google Scholar
• Takizawa M, Sugane K, Agematsu K. Role of tonsillar IgD+CD27+ memory B cells in humoral immunity against pneumococcal infection. Hum Immunol 2006;67(12):966-75
   PubMedGoogle Scholar
• Moens L, Wuyts M, Meyts I, et al. Human memory B lymphocyte subsets fulfill distinct roles in the anti-polysaccharide and anti-protein immune response. J Immunol 2008;181(8):5306-12
   PubMedGoogle Scholar
• Tangye SG, Good KL. Human IgM+CD27+ B cells: memory B cells or “memory” B cells? J Immunol 2007;179(1):13-19
   PubMedGoogle Scholar
• Timens W, Boes A, Rozeboom-Uiterwijk T, Poppema S. Immaturity of the human splenic marginal zone in infancy. Possible contribution to the deficient infant immune response. J Immunol 1989;143(10):3200-6
   PubMed Web of Science ®Google Scholar
• Zandvoort A, Lodewijk ME, de Boer NK, et al.27 expression in the human splenic marginal zone: the infant marginal zone is populated by naive B cells. Tissue Antigens 2001;58(4):234-42
   PubMedGoogle Scholar
• Baumgarth N. The double life of a B-1 cell: self-reactivity selects for protective effector functions. Nat Rev Immunol 2011;11(1):34-46
   PubMed Web of Science ®Google Scholar
• Rothstein TL, Griffin DO, Holodick NE, et al. Human B-1 cells take the stage. Ann N Y Acad Sci 2013;1285:97-114
   PubMed Web of Science ®Google Scholar
• Griffin DO, Holodick NE, Rothstein TL. Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70. J Exp Med 2011;208(1):67-80
   PubMed Web of Science ®Google Scholar
• Verbinnen B, Covens K, Moens L, et al. Human CD20+CD43+CD27+CD5- B cells generate antibodies to capsular polysaccharides of Streptococcus pneumoniae. J Allergy Clin Immunol 2012;130(1):272-5
   PubMedGoogle Scholar
• Leggat DJ, Khaskhely NM, Iyer AS, et al. Pneumococcal polysaccharide vaccination induces polysaccharide-specific B cells in adult peripheral blood expressing CD19(+)CD20(+)CD3(-)CD70(-)CD27(+)IgM(+)CD43(+)CD5(+)/(-). Vaccine 2013;31(41):4632-40
   PubMedGoogle Scholar
• Haas KM, Poe JC, Steeber DA, Tedder TF. B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae. Immunity 2005;23(1):7-18
   PubMed Web of Science ®Google Scholar
• Covens K, Verbinnen B, Geukens N, et al. Characterization of proposed human B-1 cells reveals pre-plasmablast phenotype. Blood 2013;121(26):5176-83
   PubMed Web of Science ®Google Scholar
• Descatoire M, Weill JC, Reynaud CA, Weller S. A human equivalent of mouse B-1 cells? J Exp Med 2011;208(13):2563-4
   PubMed Web of Science ®Google Scholar
• Perez-Andres M, Grosserichter-Wagener C, Teodosio C, et al. The nature of circulating CD27+CD43+ B cells. J Exp Med 2011;208(13):2565-6
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010;201(1):32-41
   PubMed Web of Science ®Google Scholar
• Griffin MR, Zhu Y, Moore MR, et al. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 2013;369(2):155-63
   PubMed Web of Science ®Google Scholar
• Simonsen L, Taylor RJ, Schuck-Paim C, et al. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. Lancet Respir Med 2014;2(5):387-94
   PubMed Web of Science ®Google Scholar
• Weil-Olivier C, Gaillat J. Can the success of pneumococcal conjugate vaccines for the prevention of pneumococcal diseases in children be extrapolated to adults? Vaccine 2014;32(18):2022-6
   PubMedGoogle Scholar
• Link-Gelles R, Taylor T, Moore MR; Active Bacterial Core Surveillance T. Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020. Vaccine 2013;31(22):2572-7
   PubMed Web of Science ®Google Scholar
• Paradiso PR. Pneumococcal conjugate vaccine for adults: a new paradigm. Clin Infect Dis 2012;55(2):259-64
   PubMed Web of Science ®Google Scholar
• Musher DM, Sampath R, Rodriguez-Barradas MC. The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence? Clin Infect Dis 2011;52(5):633-40
   PubMed Web of Science ®Google Scholar
• Vila-Corcoles A, Ochoa-Gondar O. Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice. Drugs Aging 2013;30(5):263-76
   PubMedGoogle Scholar
• Vila-Corcoles A. Advances in pneumococcal vaccines: what are the advantages for the elderly? Drugs Aging 2007;24(10):791-800
   PubMedGoogle Scholar
• Jackson LA, Neuzil KM, Nahm MH, et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2007;25(20):4029-37
   Google Scholar
• de Roux A, Schmole-Thoma B, Siber GR, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008;46(7):1015-23
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Southern J, Andrews N, et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis 2009;49(9):1318-25
   PubMed Web of Science ®Google Scholar
• Ridda I, Macintyre CR, Lindley R, et al. Immunological responses to pneumococcal vaccine in frail older people. Vaccine 2009;27(10):1628-36
   PubMed Web of Science ®Google Scholar
• Musher DM, Rueda AM, Nahm MH, et al. Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J Infect Dis 2008;198(7):1019-27
   PubMedGoogle Scholar
• Grabenstein JD, Manoff SB. Pneumococcal vaccines in adults: assessing the evolving evidence. Vaccine 2011;29(37):6149-54
   PubMedGoogle Scholar
• Baxendale HE, Keating SM, Johnson M, et al. The early kinetics of circulating pneumococcal-specific memory B cells following pneumococcal conjugate and plain polysaccharide vaccines in the elderly. Vaccine 2010;28(30):4763-70
   PubMed Web of Science ®Google Scholar
• Baxendale HE, Johnson M, Keating SM, et al. Circulating pneumococcal specific plasma and memory B cells in the elderly two years after pneumococcal conjugate versus polysaccharide vaccination. Vaccine 2010;28(42):6915-22
   PubMedGoogle Scholar
• Hak E, Grobbee DE, Sanders EA, et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008;66(9):378-83
   PubMed Web of Science ®Google Scholar
• Pilishvili T. Considerations for age-based recommendations for pneumococcal conjugate vaccine for adults. In: Advisory Committee on Immunization Practices. 2014. Available from: www.cdc.gov/vaccines/acip/meetings/downloads/slides-2014-06/PCV13-03-Pilishvili.pdf
   Google Scholar
• Annals of Long-Term Care. ACIP passes recommendations on pneumonia vaccine. 2014. Available from: www.annalsoflongtermcare.com/news/acip-pneumonia-vaccine-recommendations
   Google Scholar
• Lazarus R, Clutterbuck E, Yu LM, et al. A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults. Clin Infect Dis 2011;52(6):736-42
   PubMed Web of Science ®Google Scholar
• Pedersen RH, Lohse N, Ostergaard L, Sogaard OS. The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review. HIV Med 2011;12(6):323-33
   PubMed Web of Science ®Google Scholar
• Miyaji EN, Oliveira ML, Carvalho E, Ho PL. Serotype-independent pneumococcal vaccines. Cell Mol Life Sci 2013;70(18):3303-26
   PubMed Web of Science ®Google Scholar
• Feldman C, Anderson R. Review: Current and new generation pneumococcal vaccines. J Infect 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Frey SE, Lottenbach KR, Hill H, et al. A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA. Vaccine 2013;31(42):4874-80
   PubMed Web of Science ®Google Scholar
• Kong IG, Sato A, Yuki Y, et al. Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae. Infect Immun 2013;81(5):1625-34
   PubMed Web of Science ®Google Scholar
• Bologa M, Kamtchoua T, Hopfer R, et al. Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine. Vaccine 2012;30(52):7461-8
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Devaster JM, Leroux-Roels G, et al. Adjuvant system AS02 enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: randomised, controlled trials. Vaccine 2013. [Epub ahead of print]
   Google Scholar
• Lu YJ, Leite L, Goncalves VM, et al. GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis. Vaccine 2010;28(47):7468-75
   PubMed Web of Science ®Google Scholar
• Moffitt KL, Yadav P, Weinberger DM, et al. Broad antibody and T cell reactivity induced by a pneumococcal whole-cell vaccine. Vaccine 2012;30(29):4316-22
   PubMed Web of Science ®Google Scholar
• Goncalves VM, Dias WO, Campos IB, et al. Development of a whole cell pneumococcal vaccine: BPL inactivation, cGMP production, and stability. Vaccine 2014;32(9):1113-20
   PubMed Web of Science ®Google Scholar
• Ferreira DM, Neill DR, Bangert M, et al. Controlled human infection and rechallenge with Streptococcus pneumoniae reveals the protective efficacy of carriage in healthy adults. Am J Respir Crit Care Med 2013;187(8):855-64
   PubMed Web of Science ®Google Scholar
• Pauksens K, Nilsson AC, Caubet M, et al. Randomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02V in elderly adults. Clin Vaccine Immunol 2014;21(5):651-60
   PubMed Web of Science ®Google Scholar
• Prymula R, Pazdiora P, Traskine M, et al. Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: a phase II randomized clinical trial. Vaccine 2014;32(25):3025-34
   PubMed Web of Science ®Google Scholar
• Sogaard OS, Lohse N, Harboe ZB, et al. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. Clin Infect Dis 2010;51(1):42-50
   PubMed Web of Science ®Google Scholar